Full video transcriptClick to expand
Auto-generated transcript of @drjonesdc's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Ladies, did you know there's a peptide that you can take that alleviates the various
- 0:06metapauseal issues that prevent you from getting into these core lifestyle interventions
- 0:10that you need to be doing to reverse the issues to begin with?
- 0:13And we're going to get into this one.
- 0:14And we did it in my channel.
- 0:15Hi, I'm Dr. Jones DC, a holistic obesity expert.
- 0:18What we know when you hit metapause, we have the market decrease in production of sex
- 0:22hormones.
- 0:23But what we also see is an increase in insulin resistance and inflammation.
- 0:28This is why we see belly fat storage increase.
- 0:30This is why we see this struggle and issue with being able to balance and keep the weight
- 0:35off or maybe we even start gaining weight.
- 0:38How do we fix insulin resistance?
- 0:39Well, one of the best strategies is to get into some fasting and low carb protocols.
- 0:43But wait, I've been metapause.
- 0:45I can't do the fasting.
- 0:46It becomes an issue.
- 0:47And while that is true, sometimes you can get away with it.
- 0:50You really can't get into those deep aspects of keto and fasting because of the issues
- 0:54that metapause presents.
- 0:56But AOD-9604 is your ticket to mobilizing body fat.
- 1:00And it's that inability that the insulin resistance for metapause produces and the AOD will actually
- 1:06bridge the gap and mobilize fat.
- 1:08So it'll be your ticket to achieving stability with metapause, which includes managing your
- 1:13weight and maintaining a good health for the rest of your life.
- 1:15If you guys are curious about how AOD can work, shoot us a text message and we'll see you
- 1:19guys later.
@drjonesdc's menopause peptide claims need scrutiny
Quick answer
AOD-9604 is a synthetic 16-amino acid fragment of human growth hormone (hGH176-191) that was investigated as a pharmaceutical obesity treatment in the early 2000s but failed to demonstrate significant weight loss over placebo in Phase 2b/3 human trials. It is not FDA-approved for any indication, and its use in menopausal metabolic management has no published clinical trial support. The menopause-related metabolic changes described in the video are physiologically real, but connecting them to AOD-9604 as a therapeutic solution requires evidence that does not currently exist in peer-reviewed literature.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @drjonesdc's menopause peptide claims need scrutiny, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism in obese and beta3-AR knockout mice
Mouse study; AOD9604 affected fat metabolism in mice, but the subsequent human obesity efficacy trial reported no meaningful weight loss versus placebo.
PubMed
Increase of fat oxidation and weight loss in obese mice by a modified C-terminal GH fragment
Obese-mouse study of the AOD9604 fragment; preclinical only, and these effects were not reproduced in human obesity trials.
PubMed
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
@drjonesdc's menopause peptide claims need scrutiny is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "@drjonesdc's menopause peptide claims need scrutiny" from Lasting Weight Loss. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: AOD-9604 is a synthetic 16-amino acid fragment of human growth hormone (hGH176-191) that was investigated as a pharmaceutical obesity treatment in the early 2000s but failed to demonstrate significant weight loss over placebo in Phase 2b/3 human trials.
The reason this review is not generic is the source wording and the canonical claim label "peptides the one peptide you need to be taking for menopausal symptom." In this clip, the useful excerpt is: "Ladies, did you know there's a peptide that you can take that alleviates the various metapauseal issues that prevent you from getting into these core lifestyle interventions that you need to be doing to reverse the issues to begin with?" That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism in obese and beta3-AR knockout mice (2001), Increase of fat oxidation and weight loss in obese mice by a modified C-terminal GH fragment (2001), and Gateways to clinical trials (2005), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
AOD-9604 is a synthetic 16-amino acid fragment of human growth hormone (hGH176-191) that was investigated as a pharmaceutical obesity treatment in the early 2000s but failed to demonstrate significant weight loss over placebo in Phase 2b/3 human trials.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- AOD-9604 is a synthetic 16-amino acid fragment of human growth hormone (hGH176-191) that was investigated as a pharmaceutical obesity treatment in the early 2000s but failed to demonstrate significant weight loss over placebo in Phase 2b/3 human trials. It is not FDA-approved for any indication, and its use in menopausal metabolic management has no published clinical trial support. The menopause-related metabolic changes described in the video are physiologically real, but connecting them to AOD-9604 as a therapeutic solution requires evidence that does not currently exist in peer-reviewed literature.
- AOD-9604 failed to beat placebo for weight loss in its Phase 2b/3 human trials (Ng et al., 2000, International Journal of Obesity) and was never FDA-approved for obesity or any other indication.
- Zero published randomized controlled trials have tested AOD-9604 specifically in menopausal women for weight management or metabolic health.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- AOD-9604 failed to beat placebo for weight loss in its Phase 2b/3 human trials (Ng et al., 2000, International Journal of Obesity) and was never FDA-approved for obesity or any other indication.
- Zero published randomized controlled trials have tested AOD-9604 specifically in menopausal women for weight management or metabolic health.
- The menopause-related metabolic claims in the video are grounded in real science: estrogen loss does increase insulin resistance and visceral fat, per Mauvais-Jarvis et al. (2013, Endocrine Reviews).
- AOD-9604 is available only through compounding pharmacies in the US, which places it outside standard FDA drug approval pathways and introduces consistency and safety unknowns.
- Interventions with actual clinical evidence for menopausal metabolic health include resistance training (Bea et al., 2010, Menopause) and, in appropriate candidates, hormone therapy (Stuenkel et al., 2015, Journal of Clinical Endocrinology and Metabolism).
- A DC (Doctor of Chiropractic) credential does not confer prescriptive authority over peptide compounds in most US states, and the video does not acknowledge this scope-of-practice limitation.
- Mechanism-based reasoning, the idea that a compound should work based on its proposed biological pathway, is not a substitute for clinical trial evidence, and AOD-9604 is a textbook example of a compound with a plausible mechanism that still failed in human trials.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @drjonesdc actually say?
The creator claims that AOD-9604, a synthetic peptide fragment derived from human growth hormone, can "mobilize body fat" in menopausal women and "bridge the gap" when insulin resistance makes fasting and low-carb diets difficult. The pitch is that menopause-related hormonal decline causes insulin resistance and fat accumulation, that typical dietary interventions like keto and intermittent fasting become harder to tolerate in menopause, and that AOD-9604 solves this by acting as a fat-mobilizing shortcut. The call to action is a text message inquiry, which is a direct commercial solicitation. Worth flagging upfront: "metapause" is not a medical term. The correct term is menopause, and using a non-standard word 11 times in a short video does not inspire clinical confidence.
Does the science back this up?
Mostly, no. AOD-9604 has a thin and mostly disappointing clinical record. The peptide was originally developed by Metabolic Pharmaceuticals as an obesity drug. Early animal studies were promising, but the human trials did not hold up. The pivotal Phase 2b/3 trials (Ng et al., 2000, International Journal of Obesity) found no statistically significant weight loss compared to placebo in obese adults. The drug failed to achieve FDA approval for obesity. There is zero peer-reviewed clinical evidence specifically in menopausal women. The insulin resistance framing is partially grounded in real physiology, but the leap to AOD-9604 as the fix is not supported by any published human trial data in this population.
What did they get wrong (or right)?
Credit where it is due: the claim that menopause is associated with increased insulin resistance and visceral fat accumulation is accurate and well-documented. Mauvais-Jarvis et al. (2013, Endocrine Reviews) confirmed that estrogen loss drives metabolic dysfunction, and that this creates real barriers to standard dietary interventions. The observation that fasting and low-carb protocols can be harder for some menopausal women due to cortisol dysregulation and sleep disruption is also a reasonable clinical observation, though it is overstated here as a blanket rule.
What they got wrong is the conclusion. The logic jumps from a real problem to an unsupported solution. Calling AOD-9604 "your ticket" to metabolic stability in menopause is not backed by any clinical trial in this population. The FDA reviewed this compound and did not approve it. Framing a failed pharmaceutical candidate as a wellness shortcut for menopausal women is misleading, regardless of the clinical credential attached to the name.
- Real: menopause increases insulin resistance and fat storage
- Real: some dietary strategies are harder to sustain in menopause
- Not real: AOD-9604 has demonstrated clinical efficacy for this in humans
- Not addressed: safety profile, regulatory status, or compounding considerations
What should you actually know?
AOD-9604 is not FDA-approved for any indication. It is available through compounding pharmacies in the US, which means it exists in a regulatory gray zone. The FDA has previously issued warning letters related to compounded AOD-9604 products. There are no published randomized controlled trials specifically examining AOD-9604 in menopausal women. The compound's proposed mechanism involves activating lipolysis through beta-3 adrenergic receptors, which sounds plausible in theory, but mechanism is not efficacy. Many compounds have logical mechanisms and still fail in trials, which is exactly what happened here.
If you are a menopausal woman struggling with weight and metabolic health, there are interventions with actual evidence behind them: resistance training (Bea et al., 2010, Menopause), hormone therapy in appropriate candidates (Stuenkel et al., 2015, Journal of Clinical Endocrinology and Metabolism), and structured dietary support. A DC credential, while legitimate for certain scopes of practice, does not confer prescriptive authority over peptide therapies in most US states, and that context is absent from this video entirely.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Lasting Weight Loss · TikTok creator
29.2K views on this video
The ONE peptide you NEED to be taking for menopausal symptoms! #fyp #menopause #foryoupagе #tipsandtricks #fypシ #peptide #xybzca #drjones #doctorjones
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about aod-9604 failed to beat placebo for weight loss in its?
AOD-9604 failed to beat placebo for weight loss in its Phase 2b/3 human trials (Ng et al., 2000, International Journal of Obesity) and was never FDA-approved for obesity or any other indication.
What does the video say about zero published randomized controlled trials have tested aod-9604 specifically in?
Zero published randomized controlled trials have tested AOD-9604 specifically in menopausal women for weight management or metabolic health.
What does the video say about the menopause-related metabolic claims in the video?
The menopause-related metabolic claims in the video are grounded in real science: estrogen loss does increase insulin resistance and visceral fat, per Mauvais-Jarvis et al. (2013, Endocrine Reviews).
What does the video say about aod-9604?
AOD-9604 is available only through compounding pharmacies in the US, which places it outside standard FDA drug approval pathways and introduces consistency and safety unknowns.
What does the video say about interventions with actual clinical evidence for menopausal metabolic health include?
Interventions with actual clinical evidence for menopausal metabolic health include resistance training (Bea et al., 2010, Menopause) and, in appropriate candidates, hormone therapy (Stuenkel et al., 2015, Journal of Clinical Endocrinology and Metabolism).
What does the video say about a dc (doctor of chiropractic) credential does not confer prescriptive?
A DC (Doctor of Chiropractic) credential does not confer prescriptive authority over peptide compounds in most US states, and the video does not acknowledge this scope-of-practice limitation.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Lasting Weight Loss, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.